Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fate Therapeutics (FATE) Debt to Equity (2016 - 2019)

Fate Therapeutics' Debt to Equity history spans 8 years, with the latest figure at $0.05 for Q3 2019.

  • For Q3 2019, Debt to Equity fell 39.18% year-over-year to $0.05; the TTM value through Sep 2019 reached $0.05, down 39.18%, while the annual FY2018 figure was $0.09, 51.65% down from the prior year.
  • Debt to Equity reached $0.05 in Q3 2019 per FATE's latest filing, down from $0.12 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.93 in Q1 2015 to a low of $0.05 in Q3 2019.
  • Average Debt to Equity over 5 years is $0.3, with a median of $0.23 recorded in 2018.
  • Peak YoY movement for Debt to Equity: surged 3272.26% in 2015, then tumbled 80.77% in 2017.
  • A 5-year view of Debt to Equity shows it stood at $0.48 in 2015, then crashed by 69.53% to $0.15 in 2016, then skyrocketed by 31.31% to $0.19 in 2017, then tumbled by 51.65% to $0.09 in 2018, then crashed by 43.96% to $0.05 in 2019.
  • Per Business Quant, the three most recent readings for FATE's Debt to Equity are $0.05 (Q3 2019), $0.12 (Q2 2019), and $0.1 (Q1 2019).